Questions About Cancer? 1-800-4-CANCER

Childhood Rhabdomyosarcoma Treatment (PDQ®)

Health Professional Version
Last Modified: 11/26/2013

Changes to This Summary (11/26/2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Cellular Classification

Added Skapek et al. as reference 27.

Recurrent Childhood Rhabdomyosarcoma

Added text to state that in a retrospective review from the German Cooperative Soft Tissue Sarcoma Group, patients with alveolar rhabdomyosarcoma who relapsed with a single-disease focus and who received subsequent multiagent chemotherapy plus adequate local-relapse therapy had a better probability of long-term disease control than did patients with disseminated recurrences and/or tumors treated without adequate local-relapse therapy (cited Dantonello et al. as reference 7 and level of evidence 3iiA).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.